Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$1 | -$0 |
| % Margin | – | – | -88.6% | – |
| R&D Expenses | $2 | $2 | $2 | $1 |
| G&A Expenses | $1 | $2 | $2 | $2 |
| SG&A Expenses | $1 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$2 | -$0 |
| Operating Expenses | $4 | $4 | $2 | $3 |
| Operating Income | -$4 | -$4 | -$3 | -$3 |
| % Margin | – | – | -284.9% | – |
| Other Income/Exp. Net | $0 | $1 | -$0 | $0 |
| Pre-Tax Income | -$4 | -$3 | -$3 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$3 | -$3 | -$3 |
| % Margin | – | – | -316.1% | – |
| EPS | -0.95 | -0.89 | -1.56 | -4.81 |
| % Growth | -6.7% | 42.9% | 67.6% | – |
| EPS Diluted | -0.95 | -0.89 | -1.56 | -4.81 |
| Weighted Avg Shares Out | 4 | 4 | 2 | 1 |
| Weighted Avg Shares Out Dil | 4 | 4 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$3 | -$3 |
| % Margin | – | – | -282.7% | – |